Upfront Briefing
Zydus’ Sentynl took an option on Mereo’s alvelestat in a package that tops out at $475M — an oral swing at alpha-1, where the standard of care is still a weekly IV drip. AbbVie, Novartis and Bristol Myers, meanwhile, took Illinois to court over 340B, and Epicrispr pulled $90M out of the crossover crowd. Translation: capital is going to rare disease with a clear incumbent to displace, and the fight over who captures the discount has moved from Washington to the state courts. One of those is a pricing question wearing a constitutional costume.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,728.2 |
(0.3%) |
12.7% |
| Nasdaq 100 |
29,525.5 |
(0.3%) |
17.1% |
| Russell 2000 |
3,027.1 |
0.3% |
20.7% |
| Healthcare (XLV) |
168.0 |
(0.3%) |
8.0% |
| Biotech (XBI) |
158.1 |
0.0% |
30.1% |
| Nasdaq Biotech (NBI) |
6,849.9 |
(0.1%) |
20.0% |
| Clinical Trials (BBC) |
52.3 |
0.0% |
39.0% |
|
- Biotech outperformed with XBI flat against a 0.3% S&P 500 decline, with the day’s flow in deals and private capital — Sentynl’s $475M option on Mereo’s alvelestat and Epicrispr’s $90M crossover-led Series C — rather than in large-cap tape.
- The broad tape slipped on energy risk rather than rates: US crude settled near $83 after Iran reiterated it will keep the Strait of Hormuz closed, while the 10-year eased 3bp to 4.67% ahead of the July CPI print due Wednesday 12 August.
- Market data: U.S. cash close Tuesday, 11 August 2026.
The Big 3
|
1
|
Zydus’ Sentynl options US rights to Mereo’s alvelestat in a $475M package |
- Sentynl Therapeutics, a Zydus Lifesciences subsidiary, took an option to commercialise alvelestat in the US — an oral neutrophil elastase inhibitor that Mereo BioPharma has readied for global Phase 3 in alpha-1 antitrypsin deficiency-associated lung disease.
- Why it matters: Structure matters more than the headline here. Sentynl holds an option, not a licence: an undisclosed payment now, then $40M in upfront and R&D money only if it exercises, with up to $435M in milestones and double-digit tiered royalties behind that. Mereo keeps rest-of-world rights and runs the global Phase 3 itself, so the cash-burn question is unresolved. Mereo bought alvelestat from AstraZeneca for $5M upfront in 2017 — a good return on a shelved asset. The competitive frame is augmentation therapy: weekly IV pooled-plasma AAT from Grifols, CSL and Takeda is the only approved option, and an oral neutrophil elastase inhibitor attacks that franchise directly if Phase 3 delivers.
- Source: Fierce Biotech
- More: GlobeNewswire
|
|
2
|
AbbVie, Novartis and BMS sue Illinois over its 340B contract-pharmacy law |
- AbbVie, Novartis and Bristol Myers Squibb filed separate suits in the Northern District of Illinois seeking to block HB 2371, which took effect 7 August and bars manufacturers from restricting 340B contract-pharmacy arrangements.
- Why it matters: HB 2371 took effect 7 August and bars manufacturers from restricting 340B contract-pharmacy arrangements; AbbVie and Novartis filed in the Northern District of Illinois on the 10th, with Bristol Myers following. The argument is preemption and takings — Illinois forces discounted units through commercial pharmacies that federal law never named as covered entities. Illinois is at least the fourteenth state to draw suit, so the read-through is the aggregate: gross-to-net erosion across every large-cap US portfolio, not a single-state item. AbbVie, headquartered in Chicago, carries the most direct exposure. Watch for a preliminary-injunction ruling, which is the near-term catalyst; a denial here would accelerate copycat statutes into 2027 budgeting.
- Source: Endpoints
- More: Bloomberg Law; Courthouse News
|
| 3 | Epicrispr lands $90M crossover round on three-patient FSHD signal |
- Epicrispr closed an oversubscribed $90M Series C co-led by Octagon Capital and Janus Henderson to push EPI-321, an AAV-delivered epigenetic silencer of DUX4, toward registrational studies in facioscapulohumeral muscular dystrophy.
- Why it matters: Octagon Capital and Janus Henderson co-led, with Fidelity, Cormorant, Duquesne, Sanofi Ventures, abrdn, Angelini and Readout filling the book — a crossover-heavy syndicate that prices Epicrispr for a pivotal rather than another platform extension. The clinical case is still thin: three patients gained 0.5–1.3 pounds of lean muscle six months after a single infusion of EPI-321, a directional read and nothing more. The competitive set is unforgiving. Novartis owns Phase 3 delpacibart braxlosiran through its $12B Avidity takeout, Sarepta has an siRNA in Phase 1/2, and Scholar Rock recently started Phase 2. Epicrispr’s differentiation is mechanistic — silence DUX4 without cutting DNA. Full Phase 1/2 data land later this year and settle whether the crossover book was early or wrong.
- Source: Endpoints
- More: BioPharma Dive; Fierce Biotech
|
Everything Else that broke
- China’s NMPA accepted Laekna’s NDA for afuresertib (LAE002), an oral pan-AKT inhibitor, in combination with paclitaxel for platinum-resistant ovarian cancer. — PR Newswire
- FDA will open applications in September for its proposed expedited IND pilot, aiming to select up to 10 sponsor–institution pairs by year-end. — Endpoints
- Abbott and Google Health are building a consumer app pairing biowearable data with AI-generated health insights. — Fierce Biotech
- July FDA approvals included six novel drugs and first products for three biotechs. — BioCentury
- Researchers questioned Exelixis’ cabozantinib lifecycle strategy near a patent cliff. — Endpoints
- Hims said it could move quickly if FDA allows six wellness peptides. — Endpoints
- Amgen is building out a new R&D center in Hyderabad. — Fierce Biotech
- Aura and Schrödinger cut jobs as restructuring stays in vogue. — BioSpace
- AI biotechs are pushing a faster fail-fast model for drug development. — BioSpace
- Two health insurers offered an AI reality check despite rising spend. — Endpoints
- Galvanize began first commercial procedures with its Aliya EX system. — PR Newswire
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Sentynl Therapeutics (Zydus Lifesciences) optioned US rights to Mereo BioPharma’s alvelestat for AATD-LD, worth up to $475M including $40M on exercise plus double-digit tiered royalties (see The Big 3). — Fierce Biotech
VC / Private Financings
- Epicrispr raised a $90M Series C co-led by Octagon Capital and Janus Henderson, joined by Fidelity, Cormorant, Duquesne and Sanofi Ventures (see The Big 3). — Endpoints
- Infinimmune raised a $75M Series A led by Regeneron Ventures to back two atopic dermatitis antibodies. — BioPharma Dive
- Vaderis Therapeutics closed an oversubscribed $152M Series B to fund a Phase 3 study of its AKT inhibitor in hereditary haemorrhagic telangiectasia. — Fierce Biotech
- K2 Therapeutics disclosed $50M in seed financing from founder MPM BioImpact alongside the appointment of ex-Legend Biotech CEO Ying Huang; a $250M Series A is targeted but not raised. — Endpoints
IPOs / Follow-Ons
- No notable IPOs or follow-ons in the last 24 hours.
Academic Corner - Daraxonrasib resistance data in 44 pancreatic cancer patients pointed to rational combination strategies. — Nature Medicine
- Nature Medicine argued anti-aging interventions need stronger clinical evidence and less hype. — Nature Medicine
|
